Wird geladen...
Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome
Enasidenib is an FDA-approved isocitrate dehydrogenase 2 (IDH2) inhibitor, which is used in the treatment of acute myeloid leukemia (AML). We present a case of AML with an IDH2 mutation treated with a regimen of enasidenib and 5-azacitidine, where thyroiditis was noted to be a part of differentiatio...
Gespeichert in:
| Veröffentlicht in: | Case Rep Oncol |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
S. Karger AG
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7275196/ https://ncbi.nlm.nih.gov/pubmed/32547385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000507613 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|